Top

Published in:

01-09-2015 | Editorial

Immune checkpoint targeting as anti-cancer immunotherapy: promises, questions, challenges and the need for predictive biomarkers at ASCO 2015

Authors: Hardev Pandha, Graham Pawelec

Published in: Cancer Immunology, Immunotherapy | Issue 9/2015

Abstract

Immunotherapy targeting “immune checkpoints” first made the headlines at the ASCO (American Society of Clinical Oncology) Annual Meeting in 2013, took centre stage at 2014 and consolidated its position as a potentially curative first-line therapy as reflected by the presentations at ASCO 2015. For the first time, previously refractory cancers are proving amenable to treatment, but still only a fraction, usually a minority, of patients respond. The hunt for factors predicting responses and for biomarkers to monitor treatment was a major theme of this year’s meeting, as briefly discussed in this Editorial.

Ai M, Curran MA (2015) Immune checkpoint combinations from mouse to man. Cancer Immunol Immunother 64(7):885–892. doi:10.1007/s00262-014-1650-8 CrossRefPubMed

Postow MA, Callahan MK, Wolchok JD (2015) Immune checkpoint blockade in cancer therapy. J Clin Oncol 33(17):1974–1982CrossRefPubMed

Haanen JB, Hv Thienen, Blank CU (2015) Toxicity patterns with immunomodulating antibodies and their combinations. Semin Oncol 42(3):423–428. doi:10.1053/j.seminoncol.2015.02.011 CrossRefPubMed

Weber JS, Yang JC, Atkins MB, Disis ML (2015) Toxicities of immunotherapy for the practitioner. J Clin Oncol 33(18):2092–2099. doi:10.1200/JCO.2014.60.0379 CrossRefPubMed

Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23–34. doi:10.1056/NEJMoa1504030 CrossRefPubMed

Awad MM, Hammerman PS (2015) Durable responses with PD1 inhibition in lung and kidney cancer and the ongoing search for predictive biomarkers. J Clin Oncol 33(18):1993–1994. doi:10.1200/JCO.2015.61.4172 CrossRefPubMed

Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD1 antibody in cancer. N Engl J Med 366(26):2443–2454. doi:10.1056/NEJMoa1200690 PubMedCentralCrossRefPubMed

Kvistborg P, Philips D, Kelderman S et al (2014) Anti-CTLA4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med 6(254):254ra128. doi:10.1126/scitranslmed.3008918 CrossRefPubMed

Rizvi NA, Hellmann MD, Snyder A et al (2015) Cancer immunology. Mutational landscape determines sensitivity to PD1 blockade in non-small cell lung cancer. Science 348(6230):124–128. doi:10.1126/science.aaa1348 CrossRefPubMed

10.

Le DT, Uram JN, Wang H et al (2015) PD1 blockade in tumours with mismatch-repair deficiency. N Engl J Med 372(26):2509–2520. doi:10.1056/NEJMoa1500596 CrossRefPubMed

11.

Pico de Coaña Y, Masucci G, Hansson J, Kiessling R (2014) Myeloid-derived suppressor cells and their role in CTLA4 blockade therapy. Cancer Immunol Immunother 63(9):977–983. doi:10.1007/s00262-014-1570-7 CrossRefPubMed

12.

Castelli C, Rivoltini L, Rodolfo M, Tazzari M, Belgiovine C, Allavena P (2015) Modulation of the myeloid compartment of the immune system by angiogenic- and kinase inhibitor-targeted anti-cancer therapies. Cancer Immunol Immunother 64(1):83–89. doi:10.1007/s00262-014-1576-1 CrossRefPubMed

13.

Andtbacka RH, Kaufman HL, Collichio F et al (2015) Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol (pii: JCO.2014.58.3377 [Epub ahead of print])

14.

Becht E, Goc J, Germain C, Giraldo NA, Dieu-Nosjean MC, Sautès-Fridman C, Fridman WH (2014) Shaping of an effective immune microenvironment to and by cancer cells. Cancer Immunol Immunother 63(10):991–997. doi:10.1007/s00262-014-1590-3 CrossRefPubMed

15.

Chang S, Kohrt H, Maecker HT (2014) Monitoring the immune competence of cancer patients to predict outcome. Cancer Immunol Immunother 63(7):713–719. doi:10.1007/s00262-014-1521-3 PubMedCentralCrossRefPubMed

16.

Santegoets SJ, Dijkgraaf EM, Battaglia A et al (2015) Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. Cancer Immunol Immunother. [Epub ahead of print]

Title: Immune checkpoint targeting as anti-cancer immunotherapy: promises, questions, challenges and the need for predictive biomarkers at ASCO 2015
Authors: Hardev Pandha
Graham Pawelec
Publication date: 01-09-2015
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 9/2015
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-015-1748-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2015

The TLR-2/TLR-6 agonist macrophage-activating lipopeptide-2 augments human NK cell cytotoxicity when PGE2 production by monocytes is inhibited by a COX-2 blocker

Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas

Genetic susceptibility to cervical squamous cell carcinoma is associated with HLA-DPB1 polymorphisms in Taiwanese women

Inhibition of tumor progression during allergic airway inflammation in a murine model: significant role of TGF-β

Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients

Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model

Keynote webinar | Spotlight on antibody–drug conjugates in cancer